REFERENCES
- Mandell LA. Guidelines for community-acquired pneu-monia. A tale of 2 countries. Clin Infect Dis 2000; 31: 422–425.
- Zhanel CC, Dueck M, Hoban DJ, et al. Review of macrolide and ketolides. Drugs 2001; 61: 443–498.
- Amsden GW. Pneumococcal macrolide resistance - myth or reality? J Antimicrob Chemother 1999; 44: 1–6.
- Steigbigel NH. Macrolides and clindamycin. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Fifth ed. Churchill Livingstone. Philadelphia. 2000: 366–382.
- Lipsitch M, Levin BR. The population dynamics of antimicrobial chemotherapy. Antimicrob Agents Chemother 1997; 41: 363–373.
- Myburgh J, Nagel GJ, Petschel E. The efficacy and toler-ance of a three-day course of azithromycin in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1993; 31(Suppl E): 163–169.
- Vergis EN, Indorf A, File TM Jr, et al. Azithromycin vs cefuroxime plus erithromycin for empirical treatment of com-munity-acquired pneumonia in hospitalised patients: a prospective, randomised multicenter trial. Arch Intern Med 2000; 160: 1294–1300.
- O'Doherty B, Muller O and the Azithromycin Study Group. Randomised, multicenter study of the efficacy and tol-erance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumo-nia. Eur J Clin Microbiol Infect Dis 1998; 17: 828–833.
- Socan M. Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course. J Chemother 1998; 10: 64–8.
- Cockburn J, Gibberd RW, Reid AL, Sanson-Fisher RW. Determinants of non-compliance with short term antibiotic regimens. Br Med J 1987; 295: 814–8.